Phase I Study of Intravenously Administered Bacterially Synthesized Granulocyte-Macrophage Colony-stimulating Factor and Comparison with Subcutaneous Administration

Graham J. Lieschke, Marian O'Connor, Antony W. Burgess, George Morstyn, Darryl Maher, Katherine McGrath, Michael Green, William Sheridan, Richard M. Fox, Eric Bonnem

Research output: Contribution to journalArticleResearchpeer-review

67 Citations (Scopus)

Abstract

A Phase I study of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was undertaken in 21 patients with advanced malignancy or neutropenia. rhGM-CSF was administered once daily by i.v. bolus injection (0.3 to 3 jig/kg/ day) or 2-h i.v. infusion (3 to 20 μg/kg day) for 10 days. rhGM-CSF at all i.v. doses caused an immediate transient decrease in circulating neutrophils, eosinophils, and monocytes. By 6 h after rhGM-CSF, circulating leukocyte levels were restored. Daily i.v. bolus dosing (03 to 3 μg/kg/day) did not elevate leukocyte levels except in one neutropenic patient. Daily 2-h i.v. infusions (10 to 20 μg/kg/day) caused a dose-dependent leukocytosis with increased levels of neutrophils (up to 4.3-fold), eosinophils (up to 18-fold), and monocytes (up to 3.5-fold). Marrow aspirates showed increased proportions of promyelocytes and myelocytes during rhGM-CSF administration. Retreatment after 10 days without rhGM-CSF resulted in a more marked leukocytosis at doses ≨ 10 μg/ kg/day. Platelet levels decreased for the first 3 days and then increased during the first course of rhGM-CSF administration. Two patients with chronic lymphocytic leukemia had a transient reduction in lymphocytosis. Serum cholesterol and albumin levels decreased, and vitamin B12 levels increased during rhGM-CSF treatment. At doses of up to 15 μg/kg/day, rhGM-CSF was relatively well tolerated by the patients, but adverse effects included bone pain, lethargy, fever, rash, and weight gain. A first dose reaction characterized by hypoxia and hypotension was identified at dose levels ≥ 1 μg/kg. Dosing i.v. was less potent at inducing a leukocytosis than previously observed for equivalent s.c. doses and was associated with a higher incidence of generalized rash and first dose reactions. The maximal tolerated dose of i.v. rhGM-CSF was 15 μg/kg/day. Phase II studies in which the desired effect is to raise leukocyte levels should be undertaken at rhGM-CSF doses of 3 to 15 μg/kg/day.

Original languageEnglish
Pages (from-to)606-614
Number of pages9
JournalCancer Research
Volume50
Issue number3
Publication statusPublished - 1 Feb 1990
Externally publishedYes

Cite this